Ferring wins Nocdurna patent suit with ex-employee
25-08-2020
China approves three Gilead remdesivir patents for COVID-19 treatment
27-02-2020
J&J, HHS sign expanded deal to find COVID-19 vaccine
14-02-2020
06-02-2020
Lightspring / Shutterstock.com
A state-run institution in China has applied for a patent on the use of an experimental Gilead Sciences drug, which scientists believe may be able to fight the coronavirus outbreak that has killed hundreds.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Wuhan Institute of Virology of the China Academy of Sciences, Gilead Sciences, coronavirus, experimental drugs, remdesivir, patent application